|
n About Sars
SARS started in
Guangdong
Province in Nov 2002. After spreading for several months, it affected the population in several ten counties and districts. Over thousands people were infected. And several hundred people died from it. WHO named the disease as Severe acute respiratory syndrome, SARS.
n SARS Vaccine
 Neutralization antibody has been found in SARS patient sera, showing that man can be immunized after SARS virus infection, which provided immunological basis for artificial immunization. According to the study of WHO, SARS virus does not change as much as what we predicted before. The strain is quite stable, which makes possible the vaccine research for SARS prevention with specificity. Tentative culturing of SARS virus shows that the virus could propagate well in Vero cells. This is the precondition for the industrialization of SARS vaccine. With the above primary conclusions and experimental results, scientists around the world have started working on the development of SARS vaccine.
Inactivated vaccines, live attenuate vaccines, gene engineering subunit vaccines, and vector vaccines are the ones which could be developed. The consensus of scientists is that inactivated vaccine is the most possible vaccine as the first one successfully developed, because of its mature technology and short-term research required. China National SARS control and prevention headquarters included developing inactivated SARS vaccine, which includes the development of key R&D technologies for SARS prevention and vaccines, into “National High-tech R&D Plan (863 Plan)”. And they provided enough economic and regulatory supports. Sinovac, cooperating with CDC Disease Prevention and control Centre and
Institute of
Laboratory Animals in China Academy of Medical Science, took the responsibility of doing research and developing SARS inactivated vaccine and established BL-3 Lab.
Clinical trial certificate was issued by State Food and Drug Certificate on <Jan. 19 2004>. The result of Phase I clinical trial was announced on the conference for discovering blindness jointly held Ministry of Science and Technology, Ministry of Health, and State Food and Drug Administration on <Dec. 15 2004>. The completion of phase I clinical trial symbolizes that the difficulty of SARS vaccine development has been tackled. This is an important national achievement of science and technology project on SARS. And it’s also the world first SARS vaccine which has completed phase I clinical trial. And we continuously conduct the persistent immunization observation to those volunteers who were vaccinated in Phase I clinical trial.
n pubilc
A serological survey on neutralizing antibody titer of SARS convalescent sera
[Original]
J. Med. Virol. 77:147-150, 2005. © 2005 Wiley-Liss, Inc.
[abstract]
A seroepidemiologic study was conducted in
North China in 2003 to determine the neutralizing antibody titer of severe acute respiratory syndrome (SARS) convalescent sera. A total of 99 SARS convalescent serum samples were collected from patients from the Inner Mongolia Autonomous Region,
Hebei
Province , and
Beijing 35-180 days after the onset of symptoms. The anti-SARS antibodies were detected by enzyme-linked immunosorbent assay (ELISA), neutralization assay, and Western blot. Eighty-seven serum samples were confirmed to be positive for SARS antibodies. The neutralizing antibody titer of the 87 positive sera was analyzed quantitatively by neutralization assay. The geometric mean titer (GMT) of the 87 convalescent sera was 1:61. The Kolmogorov-Smirnov test showed that the neutralizing antibody titers conform to normal distribution, which suggests that the average anti-SARS antibody level in this study was representative of the convalescent antibody level of the SARS population. This result could be useful for the development and quality control of SARS vaccines.
[全文链接]
http://www3.interscience.wiley.com/cgi-bin/abstract/111082963/ABSTRACT
Genome sequence variation analysis of two SARS coronavirus isolates after passage in Vero cell culture
|
